-- Femasys leverages Kebomed’s pan-European distribution strength to drive adoption of FemBloc permanent birth control in France and Benelux, unlocking significant market access --ATLANTA, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced today a partnership with Kebomed, a leading European distributor of medical devices and equipment, to com ...

Addition strengthens FemSperm family of products and enables gynecologists to offer complete in-office sperm handling for FemaSeed Intratubal InseminationATLANTA, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced today a partnership with Medical Electronic Systems LLC (MES) to provide advanced sperm analysis technology. The FemSperm Analysis ...

Core Insights - Femasys Inc. has launched the FemSperm Insemination Prep Kit, enhancing the sperm preparation process for FemaSeed Intratubal Insemination, aimed at increasing revenue growth through gynecologist activation [1][2][3] - The introduction of this kit is a significant step in Femasys' strategy to penetrate the underserved fertility market, providing a streamlined in-office solution for gynecologists [2][3] Company Overview - Femasys is a biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women globally, with a patent-protected portfolio of therapeutic and diagnostic products [4] - The company’s fertility portfolio includes FemaSeed, which is positioned as a first-step infertility treatment, and FemVue, a diagnostic tool for fallopian tube assessment [4] Product Details - The FemSperm Insemination Prep Kit allows gynecologists to perform sperm preparation and offer FemaSeed Intratubal Insemination directly in their practices, addressing the needs of an estimated 10 million U.S. women facing infertility [3] - FemaSeed has demonstrated more than double the pregnancy rates of traditional intrauterine insemination (IUI) in cases of low male sperm count, making it a safer and cost-effective alternative to IVF [3][4] Market Strategy - The commercialization of FemBloc, a non-surgical permanent birth control method, has received regulatory approvals in Europe, the UK, and New Zealand, with plans for strategic partnerships to enhance market presence [5] - Femasys aims to broaden patient access to fertility treatments and strengthen its long-term revenue growth strategy by positioning FemaSeed as a first-step treatment before IVF [2][3]